Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Experimental drug tested to control advanced cancers

NCT ID NCT04504942

Summary

This study tested an experimental drug called leronlimab in patients with advanced solid tumors that had stopped responding to standard treatments. Sixteen participants received weekly injections of leronlimab, often alongside their regular chemotherapy or radiation. Researchers measured how safe the drug was, whether tumors shrank, and how long patients lived without their cancer getting worse.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR, ADULT are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Quest Clinical Research

    San Francisco, California, 94115, United States

Conditions

Explore the condition pages connected to this study.